Poseida Therapeutics guns again for IPO

After ditching an attempted IPO earlier this year in favor of another funding round, CAR-T biotech Poseida Therapeutics is happy to go again.

In April last year, the cell therapy player put the kibosh on original its IPO plans, settling instead for a $142 million series C round with more than half of the money coming from cell and gene therapy devotee Novartis.